IBDEI2KO ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,41055,1,3,0)
 ;;=3^Progressive Supranuclear Ophthalmoplegia
 ;;^UTILITY(U,$J,358.3,41055,1,4,0)
 ;;=4^G23.1
 ;;^UTILITY(U,$J,358.3,41055,2)
 ;;=^5003780
 ;;^UTILITY(U,$J,358.3,41056,0)
 ;;=Z79.2^^152^2021^1
 ;;^UTILITY(U,$J,358.3,41056,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41056,1,3,0)
 ;;=3^Antibiotics
 ;;^UTILITY(U,$J,358.3,41056,1,4,0)
 ;;=4^Z79.2
 ;;^UTILITY(U,$J,358.3,41056,2)
 ;;=^321546
 ;;^UTILITY(U,$J,358.3,41057,0)
 ;;=Z79.01^^152^2021^2
 ;;^UTILITY(U,$J,358.3,41057,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41057,1,3,0)
 ;;=3^Anticoagulants
 ;;^UTILITY(U,$J,358.3,41057,1,4,0)
 ;;=4^Z79.01
 ;;^UTILITY(U,$J,358.3,41057,2)
 ;;=^5063330
 ;;^UTILITY(U,$J,358.3,41058,0)
 ;;=Z79.02^^152^2021^3
 ;;^UTILITY(U,$J,358.3,41058,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41058,1,3,0)
 ;;=3^Antiplatelets/Antithrombotics
 ;;^UTILITY(U,$J,358.3,41058,1,4,0)
 ;;=4^Z79.02
 ;;^UTILITY(U,$J,358.3,41058,2)
 ;;=^5063331
 ;;^UTILITY(U,$J,358.3,41059,0)
 ;;=Z79.82^^152^2021^4
 ;;^UTILITY(U,$J,358.3,41059,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41059,1,3,0)
 ;;=3^Aspirin
 ;;^UTILITY(U,$J,358.3,41059,1,4,0)
 ;;=4^Z79.82
 ;;^UTILITY(U,$J,358.3,41059,2)
 ;;=^5063340
 ;;^UTILITY(U,$J,358.3,41060,0)
 ;;=Z79.4^^152^2021^6
 ;;^UTILITY(U,$J,358.3,41060,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41060,1,3,0)
 ;;=3^Insulin
 ;;^UTILITY(U,$J,358.3,41060,1,4,0)
 ;;=4^Z79.4
 ;;^UTILITY(U,$J,358.3,41060,2)
 ;;=^5063334
 ;;^UTILITY(U,$J,358.3,41061,0)
 ;;=Z79.1^^152^2021^9
 ;;^UTILITY(U,$J,358.3,41061,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41061,1,3,0)
 ;;=3^NSAID
 ;;^UTILITY(U,$J,358.3,41061,1,4,0)
 ;;=4^Z79.1
 ;;^UTILITY(U,$J,358.3,41061,2)
 ;;=^5063332
 ;;^UTILITY(U,$J,358.3,41062,0)
 ;;=Z79.891^^152^2021^8
 ;;^UTILITY(U,$J,358.3,41062,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41062,1,3,0)
 ;;=3^Long Term Opiate/Opioid Analgesic Use
 ;;^UTILITY(U,$J,358.3,41062,1,4,0)
 ;;=4^Z79.891
 ;;^UTILITY(U,$J,358.3,41062,2)
 ;;=^5063342
 ;;^UTILITY(U,$J,358.3,41063,0)
 ;;=Z79.51^^152^2021^5
 ;;^UTILITY(U,$J,358.3,41063,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41063,1,3,0)
 ;;=3^Inhaled Steroids
 ;;^UTILITY(U,$J,358.3,41063,1,4,0)
 ;;=4^Z79.51
 ;;^UTILITY(U,$J,358.3,41063,2)
 ;;=^5063335
 ;;^UTILITY(U,$J,358.3,41064,0)
 ;;=Z79.52^^152^2021^11
 ;;^UTILITY(U,$J,358.3,41064,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41064,1,3,0)
 ;;=3^Steroids-Systemic
 ;;^UTILITY(U,$J,358.3,41064,1,4,0)
 ;;=4^Z79.52
 ;;^UTILITY(U,$J,358.3,41064,2)
 ;;=^5063336
 ;;^UTILITY(U,$J,358.3,41065,0)
 ;;=Z79.899^^152^2021^7
 ;;^UTILITY(U,$J,358.3,41065,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41065,1,3,0)
 ;;=3^Long Term Current Drug Therapy NEC
 ;;^UTILITY(U,$J,358.3,41065,1,4,0)
 ;;=4^Z79.899
 ;;^UTILITY(U,$J,358.3,41065,2)
 ;;=^5063343
 ;;^UTILITY(U,$J,358.3,41066,0)
 ;;=Z79.84^^152^2021^10
 ;;^UTILITY(U,$J,358.3,41066,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41066,1,3,0)
 ;;=3^Oral Hypoglycemic Drugs
 ;;^UTILITY(U,$J,358.3,41066,1,4,0)
 ;;=4^Z79.84
 ;;^UTILITY(U,$J,358.3,41066,2)
 ;;=^5140432
 ;;^UTILITY(U,$J,358.3,41067,0)
 ;;=Z90.13^^152^2022^5
 ;;^UTILITY(U,$J,358.3,41067,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41067,1,3,0)
 ;;=3^Acquired Absence of Breasts & Nipples,Bilateral
 ;;^UTILITY(U,$J,358.3,41067,1,4,0)
 ;;=4^Z90.13
 ;;^UTILITY(U,$J,358.3,41067,2)
 ;;=^5063584
 ;;^UTILITY(U,$J,358.3,41068,0)
 ;;=Z90.710^^152^2022^6
